Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Oct
06
Today In Oncology
Autonomous AI Triaged Urgent Suspected Skin Cancer Referrals in Real-World Implementation Study
ER-Positive HER2-Negative Advanced Breast Cancer: Giredestrant Plus Everolimus
Immune Cell Dysfunction Not Absence Defines Nonmelanoma Skin Cancer in Immunosuppressed Patients
Wildfire-Related Fine Particulate Matter Linked to Higher Mortality in Older Patients With Lung Cancer
Global Gaps in Cancer-Control Expenditure Data Identified
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo